KMT2A and acute myeloid leukemia: Beyond t(8;21), AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) translocations (forming the CBFB::MYH11 fusion gene), AML with monocytic differentiation, and AML with MLL (KMT2A) gene rearrangement, AML with expression of CD56 have all been shown to have a relatively high risk of developing MS (5–7).